Research Highlight | Published:

TARGETED THERAPIES

Redefining KRAS activation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original articles

    1. Moll, H. P. et al. Afatinib restrains K-RAS–driven lung tumorigenesis. Sci. Transl Med. 10, eaao2301 (2018)

    2. Kruspig, B. et al. The ERBB network facilitates KRAS-driven lung tumorigenesis. Sci. Transl Med. 10, eaao2565 (2018)

    Download references

    Author information

    Correspondence to Diana Romero.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark